Application of Apatinib After Multifaceted Therapies for Metastatic Breast Cancer

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35117814

Authors

Jue Wang

Yangyang Chen

Renwang Chen

Lu Wu

Jing Cheng

Affiliations

Soon will be listed here.

Abstract

Background: Apatinib is a small molecule tyrosine kinase inhibitor (TKI) that is taken orally and has high specificity for vascular endothelial growth factor receptor 2 (VEGFR-2). This study explored the efficacy and toxicity of apatinib in patients with metastatic breast cancer (MBC) who failed to respond to multifaceted therapy.

Methods: A total of 61 patients with MBC who were unresponsive to previous multifaceted chemotherapy were included in this study. The treatment regimens were either a combination of apatinib and chemotherapy or apatinib administered singly with a dose range of 250 mg every second day to 500 mg per day. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and toxicity were used as outcome measures.

Results: Of the 61 patients, partial response (PR) was observed in 14 patients (23.0%), stable disease (SD) was observed in 30 patients (49.2%), and progressive disease (PD) was observed in 17 patients (27.8%). The DCR was 44/61 (72.1%), and the ORR was 14/61 (23.0%). Of the 44 patients who achieved PR or SD, the median PFS was 4 months and 15 days. Patients with intracranial metastases were found to benefit from apatinib. Furthermore, 11 patients underwent next generation sequencing (NGS) and 5 of these had a P53 mutation. Of those 5 cases, the ORR and DCR were 0% and 20.0%, respectively. Of the 6 cases with wild-type P53, the ORR was 50.0%, and the DCR was 100.0%. Multivariate regression analysis found that hypertension was an independent prognostic factor of better DCR.

Conclusions: Apatinib showed good efficacy and manageable toxicity in patients with MBC that had not responded to multifaceted therapy.

Citing Articles

Low-dose apatinib in combination with chemotherapy for hormone receptor-positive, HER2-negative breast cancer with pulmonary lymphangitic carcinomatosis: A case report.

Chen L, Feng S, Chen X, Du C Medicine (Baltimore). 2024; 103(45):e40345.

PMID: 39535586 PMC: 11556957. DOI: 10.1097/MD.0000000000040345.

The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.

Huang J, Chen X, Xie X, Song L, Chen L, Lan X Cancer Med. 2024; 13(8):e7181.

PMID: 38659376 PMC: 11043681. DOI: 10.1002/cam4.7181.

The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases.

Chen X, Bai X, Xie X, Huang J, Chen L, Song L Ann Med. 2023; 55(1):2218647.

PMID: 37260331 PMC: 10236966. DOI: 10.1080/07853890.2023.2218647.

Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis.

Huang X, Hu X, Yi T Front Oncol. 2022; 12:940171.

PMID: 35978823 PMC: 9376484. DOI: 10.3389/fonc.2022.940171.

References

Barrios C, Liu M, Lee S, Vanlemmens L, Ferrero J, Tabei T . Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010; 121(1):121-31. PMC: 2855860. DOI: 10.1007/s10549-010-0788-0. View

Moreno-Aspitia A, Morton R, Hillman D, Lingle W, Rowland Jr K, Wiesenfeld M . Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol. 2008; 27(1):11-5. PMC: 2645094. DOI: 10.1200/JCO.2007.15.5242. View

DeSantis C, Ma J, Gaudet M, Newman L, Miller K, Sauer A . Breast cancer statistics, 2019. CA Cancer J Clin. 2019; 69(6):438-451. DOI: 10.3322/caac.21583. View

Zhang S . Problematic Analysis and Inadequate Toxicity Data in Phase III Apatinib Trial in Gastric Cancer. J Clin Oncol. 2016; 34(31):3821. PMC: 5477931. DOI: 10.1200/JCO.2016.67.3889. View

Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z . Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014; 135(8):1961-9. DOI: 10.1002/ijc.28829. View

Schneider B, Wang M, Radovich M, Sledge G, Badve S, Thor A . Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008; 26(28):4672-8. PMC: 2653128. DOI: 10.1200/JCO.2008.16.1612. View

Van Keymeulen A, Lee M, Ousset M, Brohee S, Rorive S, Giraddi R . Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature. 2015; 525(7567):119-23. DOI: 10.1038/nature14665. View

Zhu A, Yuan P, Wang J, Fan Y, Luo Y, Cai R . Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study. Oncol Lett. 2019; 17(6):4768-4778. PMC: 6507367. DOI: 10.3892/ol.2019.10205. View

Tang J, Li X, Liang J, Wu D, Peng L, Li X . Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study. Oncol Res. 2018; 27(6):635-641. PMC: 7848396. DOI: 10.3727/096504018X15288447760357. View

10.

Skibinski A, Kuperwasser C . The origin of breast tumor heterogeneity. Oncogene. 2015; 34(42):5309-16. PMC: 4734640. DOI: 10.1038/onc.2014.475. View

11.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

12.

Ronca R, Benkheil M, Mitola S, Struyf S, Liekens S . Tumor angiogenesis revisited: Regulators and clinical implications. Med Res Rev. 2017; 37(6):1231-1274. DOI: 10.1002/med.21452. View

13.

Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo H . Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat. 2012; 133(3):1067-75. DOI: 10.1007/s10549-012-2008-6. View

14.

Schwaederle M, Lazar V, Validire P, Hansson J, Lacroix L, Soria J . VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. Cancer Res. 2015; 75(7):1187-90. DOI: 10.1158/0008-5472.CAN-14-2305. View

15.

Tong X, Wang F, Liang S, Zhang X, He J, Chen X . Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochem Pharmacol. 2012; 83(5):586-97. DOI: 10.1016/j.bcp.2011.12.007. View

16.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

17.

Geng R, Li J . Apatinib for the treatment of gastric cancer. Expert Opin Pharmacother. 2014; 16(1):117-22. DOI: 10.1517/14656566.2015.981526. View

18.

Bai F, Jin Y, Zhang P, Chen H, Fu Y, Zhang M . Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment. Aging (Albany NY). 2019; 11(21):9328-9347. PMC: 6874454. DOI: 10.18632/aging.102373. View

19.

Mi Y, Liang Y, Huang H, Zhao H, Wu C, Wang F . Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010; 70(20):7981-91. PMC: 2969180. DOI: 10.1158/0008-5472.CAN-10-0111. View

20.

Duchnowska R, Loibl S, Jassem J . Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat Rev. 2018; 67:71-77. DOI: 10.1016/j.ctrv.2018.05.004. View